Fibroblast Growth Factor Receptor Inhibitors Decrease Proliferation of Melanoma Cell Lines and Their Activity Is...

Area of Science:

• Oncology
• Dermatology
• Molecular Biology

Background:

• Malignant melanoma remains a lethal skin cancer despite treatment advances.
• Vitamin D and its analogues have previously shown to enhance anticancer drug activity.
• Fibroblast growth factor receptors (FGFRs) are implicated in cancer progression.

Purpose of the Study:

• To investigate the efficacy of novel FGFR inhibitor CPL304110 and compare it with AZD4547 in melanoma cell lines.
• To determine if 1,25(OH)2D3 modulates the response of melanoma cells to these FGFR inhibitors.
• To explore the interplay between vitamin D signaling and FGFR inhibitor activity in melanoma.

Main Methods:

• Treatment of A375 and RPMI7951 melanoma cell lines with CPL304110 and AZD4547.
• Assessment of cell viability, cell cycle arrest, and apoptosis/necrosis.
• Evaluation of the effect of 1,25(OH)2D3 on drug efficacy and signaling pathways.
• Analysis of FGFR expression and phosphorylation.

Main Results:

• CPL304110 demonstrated potent inhibition of melanoma cell viability (IC50 < 1 µM).
• 1,25(OH)2D3 significantly enhanced CPL304110 efficacy in A375 cells but not RPMI7951 cells.
• FGFR inhibitors induced cell cycle arrest or apoptosis depending on the cell line.
• A cell-specific crosstalk between vitamin D signaling and FGFR inhibitor activity was observed.

Conclusions:

• Novel FGFR inhibitor CPL304110 is effective against melanoma cells.
• Vitamin D can potentiate the anti-melanoma effects of FGFR inhibitors in a cell-specific manner.
• The interaction between vitamin D pathways and FGFR inhibitors warrants further investigation for clinical application in melanoma treatment.